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Model-based approacha b s t r a c t
The overarching aim of work package 1 of the European Proton Therapy Network (EPTN) is to create a
firm basis for evidence-based particle therapy at the European level. To achieve this, this work package
will set up a worldwide unique prospective data registration programme for nine different tumour sites.
Such programme will provide more insights into the current practice across all European particle therapy
centres and into the results of particle therapy with regard to radiation-induced toxicity and efficacy in
terms of local control and survival.
More importantly, prospective data registration provides major opportunities to continuously improve
the quality of particle therapy, by defining bench marks, to identify best practices that may learn others
to improve quality of particle therapy, to synchronize selection criteria and to create more homogeneous
patient cohorts to evaluate results, which is particularly important in rare tumours.
This will be supported by EORTC through existing and new IT-infrastructure for data collection in dif-
ferent formats next to QA-platforms.
In addition, work package 1 will define the requirements for high quality clinical trials in order to
enhance high quality clinical trial proposals and determine alternative methods for RCT, such as the
model-based approach.
 2018 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 128 (2018) 9–13Particle therapy offers great opportunities to further broaden
the therapeutic ratio of radiotherapy by either decreasing the dose
to normal tissues while the target dose remains equivalent or by
target dose escalation without further excess dose to the normal
tissues. However, there is widespread discussion regarding lack
of evidence for proton treatment for a wide range of indications.
Even for the most widely accepted conditions, paediatric tumours,
issues remain as to whether superiority of protons over photons
has sufficiently been shown [1]. Reducing dose to normal tissues
and organs outside of target areas evidently is the key feature of
protons versus photons, but translation of these reductions into
clinically relevant benefits has still not been demonstratedconsistently, including biological issues such as variable relative
biological effectiveness [2].
Therefore, to enhance evidence-based particle therapy, EPTN
decided to establish a dedicated work package (work package 1)
to create a firm basis for evidence-based particle therapy at a Euro-
pean level. To this purpose, the following objectives were defined:
1. to determine the content of uniform prospective data registra-
tion programmes at a European level for the most common
tumour types treated with particle therapy;
2. to setup an IT infrastructure that can support the model-based
approach at a European level by harmonizing data acquisition,
making data Findable, Accessible, Interoperable and Reusable
(FAIR) and linking data from different sources and centres [9].
10 Clinical research prticle therapy3. to identify the methodological issues related to phase I and II
studies as well as to RCTs comparing photons with particles
and to define general guidelines for the design of clinical trials
to overcome these issues; to establish an Expert Committee to
advice and support researchers in Europe in the design of clin-
ical trials in particle therapy.
The aim of this paper is to further explore the background of
these objectives and to briefly discuss the strategy to further
enhance evidence-based introduction of particle therapy on a
European level.Prospective data registration
The general idea is to create a firm prospective data registration
programme for all patients treated in European particle therapy
centres which is considered important for a number of reasons:
First, major differences exist between European proton therapy
centres on criteria for patient selection, resulting in major hetero-
geneity of patient populations and eventual outcome. Prospective
data collection of all patients treated with proton therapy in Eur-
ope will provide essential information on patient mix and outcome
and may serve as a basis to discuss and harmonize selection crite-
ria for particle therapy in order to create more homogeneous
patient populations. In this way, evaluation of the efficacy of parti-
cle therapy in well-defined patient populations can be accelerated,
which is particularly useful for relatively rare tumours, such as
base of skull tumours and paediatric malignancies. Such data
may also be used as to generate hypotheses for and to design
future clinical trials.
Second, particle therapy is a relatively new radiation modality
and needs to undergo some form of quality assurance. There is
major variability in the performance between centres due to differ-
ences in delivery and treatment planning equipment, differences in
standard operation procedures (e.g. the use of image-guidance and
plan adaptation) and differences in expertise, experience, composi-
tion and treatment philosophies of the health care teams involved.
Multicentre uniform prospective data collection provides unique
opportunities to define benchmarks and to identify best practices.
This information can be used to continuously improve the quality
of particle therapy on a European level.
Third, prospective data collection is the hall mark of the model-
based approach, an evidence-based methodology introduced in the
Netherlands for both patient selection and clinical validation of
proton therapy, which could serve as an alternative for randomized
controlled trials (RCTs), which are still considered the gold stan-
dard of evidence-based medicine.
In this regard, it should be emphasized that there is no doubt
that an RCT is the most appropriate study design when the main
goal is to increase treatment efficacy in terms of local control or
survival by target dose escalation beyond the dose considered cur-
rent standard. For such an application of particles, not only the
effect of dose escalation on tumour control must be explored, but
also the risks of consequent dose escalation to the normal tissues
nearby the target beyond levels that are normally administered.
In addition, when the biological effect of particles is possibly differ-
ent from currently used photons, e.g. higher RBE when using car-
bon ions, RCTs are required not only when the primary objective
is to improve local control, but also when particles are applied to
reduce radiation-induced side effects.
It is expected that in most cases, protons will be applied to pre-
vent radiation-induced side effects and/or induction of secondary
tumours. In 2009, the Dutch Health Council produced an extensive
report on the expected indications for proton therapy and con-
cluded that around 5–10% of all patients currently treated withradiotherapy would benefit from protons, and that most (85%) of
them will be treated with particles to prevent radiation-induced
side effects and/or secondary tumour induction [3]. For the valida-
tion of radiation technologies primarily aiming at reduction of side
effects, there is a growing awareness that equating evidence-based
medicine with RCTs is an undue simplification and that other
methodologies, such as the model-based approach, are available
and need further exploitation [3,4].
Irrespective of the research question, the design of RCTs when
comparing two different radiation technologies may be subject to
methodological difficulties and pitfalls as well. Therefore, it is
important not only to identify and address these difficulties but
also to define how they can be prevented. In addition, the defini-
tion of minimal requirements for the design of RCTs comparing
photons with particles is desperately needed to guarantee general-
izability of results and eventual proper translation into routine
clinical practice.
In the Netherlands, an alternative methodology has been devel-
oped to select patients for proton therapy and to validate the ben-
efit of protons over photons: the so-called model-based approach
(MBA). The MBA is an evidence-based methodology designed to
yield evidence for a more rational selection of patients who would
most likely derive clinically relevant benefits from particle therapy
in terms of prevention of radiation-induced side effects [5,6]. The
rationale behind model-based selection is that particle therapy will
only lead to broaden the therapeutic window by decreasing toxic-
ity, when three essential requirements are met: (1) the dose to the
target is equivalent to photons and considered current standard;
(2) normal tissue sparing can be obtained with particles compared
to photons (DDose), and (3) DDose results in a clinically significant
lower complication risk (or else lower normal tissue complication
probability (DNTCP)). It should be stressed that transforming dose
into complication risk requires multivariable NTCP-models includ-
ing non-dosimetric features (e.g., patients’ age, concomitant
chemotherapy) and that therefore a decrease of dose will not
always translate into a relevant decrease of complication risks.
The key research agenda for the near future should therefore be
to validate this thesis by attempting to falsify the hypothesis that
NTCP reduction leads to less toxicity, which is the main principle
of model-based validation. In addition, it is very likely that NTCP-
models need continuous updating and adjustments due to differ-
ences in patient mix and technological evolvements [7,8]. For this
purpose, uniform prospective data registration at a European level
of all patients treated with proton therapy is essential.
Our main priority is therefore to establish uniform prospective
data registration programmes on a European level for the most
common tumour types treated with particle therapy. Therefore,
nine tumour-specific sub-tasks were established for patient groups
that are frequently treated with particle therapy, including
tumours of the central nervous system (CNS), head and neck,
breast, lung, oesophagus, lymphoma, sarcoma, prostate, and paedi-
atric cancer. Next to a generic assessment that applies for all
patients irrespective of tumour site, these sub-tasks are defining
the data sets for each tumour site.
As mentioned earlier, the main objective of the prospective data
registry is to get more information on the characteristics of
patients treated with particles and to get more insight into the
most relevant outcome measures. There is consensus that such
registry can only be informative and successful when in principle
all European particle centres will be able to participate and when
patient accrual and compliance to the programme is high. How-
ever, reality is that resources for data registries are generally lim-
ited. Therefore, EPTN decided to define different levels of data
registries to on the one hand ensure participation of all centres
and, at the other hand, offer opportunities to collect more compre-
hensive or detailed data by a limited number of centres (Table 1).
Table 1
Summary of different levels of datasets.
Level Description Status Items
Level I Minimal dataset Mandatory Minimal baseline variables
Treatment characteristics
Patient-reported outcomes (PROMs)
Minimal set of toxicity items
Utilities
Tumour control and survival
Level II More extensive dataset but still
considered standard of care
Optional Extensive sets of baseline variables
Additional PROMs
Extensive set of toxicity items
3D dose distributions, including planning CT-scans,
DICOM-RT-struct and DICOM-RT-dose
Level III More extensive dataset not considered standard
of care and requiring medical ethical approval
Optional Additional diagnostic procedures at baseline or follow up,
e.g. imaging, bio-samples, function tests
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all EPTN centres. The first version of the generic level I dataset that
applies to all patients irrespective of tumour site is outlined in
Table 2, next to an example of a tumour-specific level I dataset.
Typical examples of level I items are baseline characteristics like
gender, age, primary tumour site, stage, and other treatment
modalities used. Level I also contains PROMs such as the EORTC
QLQ-C30 to assess quality of life at baseline and at predefined time
points during follow up. Finally, items related to tumour control
and survival are considered level I as well. For breast, prostate
and lung cancer, the standard sets as defined by the International
Consortium for Health Outcomes Measurement (ICHOM) is a good
starting point (http://www.ichom.org/medical-conditions).
As particle therapy is more expensive than photon therapy,
which is an important issue in many discussions on particle ther-
apy, varying from individual patient level to discussions at the
national level, there was consensus that data supporting the eco-
nomic discussion, such as utility values measured through EQ-
5D, should also be included [10].
Level II datasets are optional and are organized into predefined
packages around a certain theme. An example of a level II dataset
could be a more comprehensive set of items related to radiation-
induced cardiac toxicity after proton therapy for breast cancer, in
which risk factors for major cardiac events at baseline and major
cardiac events during follow up are added to the minimal level I
dataset. The collection and registration of dose volume histogram
(DVH) data and/or the creation of an EPTN radiation dose registry
containing planning-CT with RT-DICOM-struct and RT-DICOM-
dose data can also be part of the level II dataset. An important fea-
ture of level II as compared to level III items is that no additional
diagnostic procedures are required apart from physician-rated tox-
icity assessment and/or PROMs.
Level III dataset are also optional and include assessments, for
which additional diagnostic procedures, beyond what is generally
considered standard of care, are needed. These assessments are
generally part of clinical observational or intervention studies,
and require formal medical ethical approval. Level III datasets are
always combined with the level I generic and level I tumour-
specific dataset and can be combined with a level II dataset. In
the example of cardiac toxicity in breast cancer patients, level III
items may include echocardiography and cardiac MRI.
The 3-level approach has several advantages. First, defining a
limited dataset (level I) requiring limited resources provides the
highest probability that all European particle centres can partici-
pate, which will provide unique and valuable information on
patient mix and different kinds of outcome. Second, level II items
can be easily added by a limited number of centres with a similar
patient mix to get more insight in the effects of particle therapy in
specific patient groups. Our experience is that patients are more
easily willing to complete additional questionnaires when addedto those that are considered standard. In addition, when PROM
assessment logistics are already in place, it is less burdensome
for centres to just add one or more questionnaires or toxicity
assessments. Third, if level I either or not combined with level II
datasets are established, it is relatively easy to integrate this in for-
mal RCTs or the concept of cohort multiple RCTs [11]. Finally, as
prospective data registration is the backbone of the model-based
approach combining level I with level II datasets will also allow
for model-based validation.
Vision and scope on clinical trials
During the EPTN meeting in April 2016, the vision and scope for
clinical trials in the EPTN were discussed and were formulated as
follows:
 Emphasis should be on performing high quality clinical trials
with properly selected patients and using relevant, validated
clinical endpoints.
 A small number of pivotal RCTs are urgently needed. However,
we need to develop, test and validate alternative evidence-
based methodologies (e.g. ‘‘cohort multiple RCTs”).
 Model-based selection (as predictive biomarker) is a useful con-
cept for NTCP-based clinical trials, and this concept should later
be extended to incorporate Tumor Control Probability (TCP) as
well.
 European centres must join forces to create such trials and evi-
dence soon.
 Trials involving state-of-the-art photon RT are welcome, as par-
ticle therapy should be an integral component of radiation
oncology.
 European trials should be open to accredited centres with
expertise and relative high numbers who wish to collaborate.
 Prospective collection of high quality data for patients treated
with proton therapy outside of clinical trials (using common
ontology and data collection forms).
 Uniform guidelines for target and organ at risk delineation, as
well as guidelines on dose constraints.
 There is a need to develop an IT-infrastructure and European QA




Particle therapy planning and delivery have changed substan-
tially over the last three decades, starting with the introduction
of passive scattered protons in the 1980s, followed by pencil beam
scanned (PBS) PT in the 1990s, to image-guided and adaptive PT
Table 2
Overview of level I generic dataset for all patients irrespective of tumour site.
Registration information
Patient Identification Number ID-number Level 1
Particle (treating) center LIST Level 1
Contact person particle center NAME Level 1
Referring center LIST Level 1
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Gender LIST Level 1
Date of birth dd/mm/yyyy Level 1
Ethnicity LIST Level 1
Educational Level LIST Level 1
Relationship status LIST Level 1
Risk factors
Smoking status LIST Level 1
Alcohol use LIST Level 1
Baseline clinical factors
WHO Performance status LIST Level 1 Level 1 Level 1 Level 1 Level 1 Level 1 Level 1
Weight kg Level 1
Height cm Level 1
Baseline tumour factor
Date of first diagnosis (first pathology) dd/mm/yyyy Level 1
Tumour site (subtask) LIST Level 1
Treatment factors index tumour
Surgery YES/NO Level 1
Radiotherapy photons YES/NO Level 1
Radiotherapy protons YES/NO Level 1
Chemotherapy YES/NO Level 1
Targeted therapy YES/NO Level 1
Immunotherapy YES/NO Level 1
Hormonal therapy YES/NO Level 1
Previous cancers and cancer treatments
Other cancer YES/NO Level 1
If YES, tumour site: LIST Level 1
If YES, when? YEAR Level 1
If YES, radiotherapy? YES/NO Level 1
If YES, previous radiotherapy,
re-irradiation?
YES/NO Level 1
Patient-reported outcome measures (PROM)
EORTC QLQ-C30 questionnaire Level 1 Level 1 Level 1 Level 1 Level 1 Level 1 Level 1
EUROQOL-5D questionnaire Level 1 Level 1 Level 1 Level 1 Level 1 Level 1 Level 1
Tumour follow up
Local recurrence YES/NO Level 1
If YES, date of local recurrence dd/mm/yyyy Level 1
Regional recurrence YES/NO Level 1
If YES, date of regional recurrence dd/mm/yyyy Level 1
Distant metastases YES/NO Level 1
If YES, date of distant metastases dd/mm/yyyy Level 1
Date of last of follow up dd/mm/yyyy Level 1
Status of last follow up LIST Level 1
12 Clinical research prticle therapycurrently, with a substantial complexity in the planning and deliv-
ery process. The evaluation of these potentially error-prone tech-
niques in clinical trials with PT require careful and thorough
quality assurance (QA) programmes, which the EORTC has pio-
neered since the 1990s. Recently, the EORTC published the results
of a facility questionnaire assessment, representing level I of QA,
for European particle centres [12]. QA in radiotherapy in general
and particle treatment in particular is defined by all of those pro-
cedures that ensure consistency of the radiation prescription and
the safe fulfilment of that prescription with regard to the dose to
the cancer and organs at risk (OARs), minimization of exposureof personnel, and patient monitoring aimed at determining the
results of treatment [13]. A QA programme is also aimed at
defining the range of acceptable deviations, detecting potential
causes for larger deviations, and developing mechanisms of
action for correction and prevention of these deviations [14]. The
goal is to reduce variability and uncertainties related to the
different steps of treatment planning and actual patient irradiation,
including but not limited to patient positioning, correct beam
delivery output and precise dose delivery to the cancer. Specific
considerations of QA for particles in a multicentre research setting
include promotion of consistency between particle centres,
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ments for a given clinical trial, ensuring accuracy and integrity of
data and importantly to assess inter-patient and inter-
institutional variation to name a few concerns. The EORTC will
bring substantial expertise in this field and offers a QA platform
and IT-support tested in numerous prospective clinical trials
assessing the efficacy of radiotherapy.
Trial methodology and support
Next to the setting up of a particle data registry and
IT-infrastructure, it is of major importance to identify the
methodological issues related to phase I, II and III studies and, in
addition, to define guidelines for the design of clinical trials on
particle therapy. Comparing different radiation technologies is
challenging and numerous methodological issues related to
clinical studies on particle therapy must be addressed. In respect
to these challenges, the EORTC will provide support to the EPTN
investigators by providing access to imaging or radiotherapy QA
platforms as mentioned in the previous paragraph, statistical
design expertise and databases that will be able to include
information from multiple sources, including but not limited
to diagnostic/molecular imaging, particle radiation therapy
parameters, prospective QA assessments, and biological
samples [15].
To advice and support clinical researchers in Europe, a plat-
form of experts will be established. To this end, an invitational
conference will be organized with experts in the field of parti-
cle therapy (radiation oncologists and medical physicists),
methodology, epidemiology and statistics. Based on the out-
come of this conference, a checklist with minimal requirements
and quality points will be created to improve consistency
between trials. This checklist can then be used to review future
studies and trial protocols. In this regard, this embarks on the
vision and scope as previously discussed within EPTN and to
embark on the work already done by the Union of Light Ion
Centres in Europe (ULICE) (http://ulice.web.cern.ch/ULICE/cms/
index.php?file=results), in particular JRA 2.2 (review of existing
protocol structure in large clinical research organization), JRA
2.3 (description of tasks with a proposal for potential structures
for clinical research) and JRA 2.6 (implementation, testing and
evaluation of the structure with typical ‘‘cases” for research
and development).
Finally, an Expert Committee (EC) will be founded with experts
in the field that can be consulted in the design of future clinical
studies on particle therapy. The EC will also be responsible for set-
ting up meetings in which future studies can be discussed. It
should be noted that (1) ESTRO/EPTN is not going to conduct clin-
ical trials but intends to use existing platforms and organizations,
and (2) external funding is needed to run such trials.Conclusion
The main objective of EPTN WP1 is to establish a uniform
prospective data registration programme for all patients treated
with particle therapy in Europe. This will be supported by
EORTC through existing and new additional QA-platforms and
IT-infrastructure for data collection with different formats. In
addition, EPTN-WP1 will define the requirements for high quality
clinical trials and set up an infrastructure for methodological
support.
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